Totipro® PE0301
Ingredient information, study findings, and product inquiries.
Totipro® Postbiotics
PE0301
Oral Care Postbiotics
A postbiotic formulation derived from three source strains (AP-32, ET-66, and LPL28), developed for oral care applications. A four-week study in 75 healthy adults measured oral bacteria and salivary immune markers; antimicrobial activity was measured separately in laboratory assays.
Pathogen Defense
In culture, inhibition reached 100% for P. gingivalis, 88% for F. nucleatum, and 49% for S. mutans; against H. pylori, the powder showed the highest coaggregation of the preparations tested (Fermentation, 2025).
Mucosal Immunity
Salivary IgA increased in the four-week human study. Fewer mouth ulcers and blisters were reported by participants in questionnaires.
Gastric Research (Preclinical)
In gastric epithelial cells under oxidative stress, wound closure with the powder was 46.79 ± 7.86% (Fermentation, 2025).
HeaLAC® Technology
Proprietary heat treatment precisely inactivates strains while preserving delicate cell components and rich bioactive metabolites.